RSV Vaccination in Stem-Cell Transplant Recipients

Hematopoietic stem-cell transplant (HSCT) recipients are at increased risk for severe disease following infection with respiratory syncytial virus (RSV). However, limited data are available on the immunogenicity, safety, and efficacy of RSV vaccines in this population. To address this gap, researchers evaluated 94 adult HSCT recipients who received the adjuvanted RSV vaccine at least 3 months posttransplant; 70% were more than 6 months posttransplant. The primary end point was seroresponse, defined as at least a fourfold rise in anti–RSV pre-F protein at 4 weeks postvaccination.